Citation Impact

1 by Nobel laureates 1 from Science/Nature 58 standout
Sub-graph 1 of 23

Citing Papers

Covalent targeted radioligands potentiate radionuclide therapy
2024 StandoutNature
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
2024 Standout
2 intermediate papers

Works of Patrick Butler being referenced

Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: Phase II study evaluating the activity of 177Lu-Octreotate peptide receptor radionuclide therapy (LuTate PRRT) and capecitabine, temozolomide CAPTEM)—First results for pancreas and updated midgut neuroendocrine tumors (pNETS, mNETS).
2020

Author Peers

Author SM PSIR Marketing SPS Last Decade Papers Cites
Patrick Butler 187 94 243 270 39 1.0k
Murali Balaji 13 20 20 121 16 245
K.-S. Li 2 105
Michal Ramon 1 15 681
Oh-Jin Kwon 141 5 13 21 21 488
Bülent Selek 5 11 274

All Works

Loading papers...

Rankless by CCL
2026